Epidermal growth factor receptor expression in 780 breast cancer patients: A reappraisal of the prognostic value based on an eight-year median follow-up

Abstract

EGFR determination is of limited value as a prognostic indicator in breast cancer.

Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer

“…It should also be mentioned that we have analyzed EGFR and AIB1 on tissue microarray, which in a study by Henriksen and co-workers were comparable to the analyses on whole sections [22]. EGFR has been found to be associated with an aggressive tumour type having prognostic value in clinical studies, including cohorts of patients treated with adjuvant chemotherapy [23][24][25]. Tsutsui and co-workers showed that patients with high EGFR and negative ER had the worst prognosis, at least in univariate analysis [24].…”

The Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 (Iressa) Suppresses c-Src and Pak1 Pathways and Invasiveness of Human Cancer Cells

“…For example, deregulation of epidermal growth factor receptor (EGFR) activation has been shown to be closely associated with head and neck and breast cancers (1)(2)(3)(4)(5). The EGFR is one of a family of four closely related receptors: EGFR (erbB1), HER2/neu (erbB2), HER3 (erbB3), and HER4 (erbB4), (Refs.…”

Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: A Hellenic Cooperative Oncology Group (HeCOG) study

“…EGFR overexpression has been associated with oestrogen receptor (ER) and progesterone receptor (PR) negativity (Pawlowski et al, 2000;Ferrero et al, 2001;Tsutsui et al, 2002;Bieche et al, 2003). Moreover, there may be an association between EGFR positivity and high histological grade or lymph node involvement, although not all existing studies are in agreement (Pawlowski et al, 2000;Ferrero et al, 2001;Witton et al, 2003;Rampaul et al, 2004;Tzaida et al, 2007). Currently, the prognostic significance of EGFR in breast cancer patients remains unclear.…”